EGFR and cancer: However, due to epistasis, this treatment has a side-effect of altering the strength of selection on other genes—e.g., making activating RAS mutations that would have been lethal in the presence of uninhibited EGFR become strongly beneficial for the cancer lineage(s) in the presence of targeted EGFR treatment.